We empower people with innovative treatment solutions

 

Key News

MARCH 13, 2024
Orexo has successfully issued secured social bonds of SEK 500 m

MARCH 8, 2024
IWD 2024 - Leading with purpose: Why Cecilia became an Orexo executive

ESG sustainable investing

Orexo has established a social financing framework

Read more

 

 

A commercial stage pharmaceutical company with three revenue generating pharmaceutical products

 

 

Development pipeline targeting large medical needs

 

 

AmorphOX® - a novel world leading nasal delivery technology leading to a new wave of products

To read all NEWS go to Media in the top menu 

Key financial figures

Group net revenue

639 MSEK
Last Twelve Months, Q123-Q423

Group EBITDA

-33 MSEK
Last Twelve Months, Q123-Q423

US Pharma segment EBIT

283 MSEK
Last Twelve Months, Q123-Q423

Cash position

171 MSEK
Q423
To read all NEWS go to Media in the top menu